TD Cowen lifts target to USD 190 for Twist Bioscience stock

Published on 10/20/2026 at 14:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen raised its target to USD 190 on October 13, 2026. Twist Bioscience stock was EUR 120.18 at Lang & Schwarz on October 20, 2026.

Target and operating scale

TD Cowen lifted its target to USD 190 on October 13, 2026.
Fiscal third-quarter revenue reached USD 118.38 million for the period ended June 30, 2026.
Twist Bioscience stock trades at EUR 120.18 at 2:14 p.m. CEST at Lang & Schwarz on October 20, 2026.

TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience (US90184D1000) is trading at EUR 120.18 at Lang & Schwarz on October 20, 2026, while TD Cowen raised its price target from USD 115 to USD 190 on October 13, 2026. According to TipRanks, the firm kept a Buy rating but warned that stronger fundamentals must validate the stock's outperformance.

Three milestones shape the story

On August 3, 2026, Twist Bioscience reported fiscal third-quarter revenue of USD 118.38 million for the period ended June 30, 2026. Revenue was up 23.20 percent from USD 96.10 million a year earlier, while gross profit reached USD 62.45 million and the gross margin was 52.80 percent, according to AI Wiki.

On August 4, 2026, Twist Bioscience announced pricing of an upsized USD 300.00 million public offering of common stock, according to the company's investor-relations page. The financing added a capital-markets consideration to the growth narrative before the October target increase.

What supports the USD 190 target?

The operating case rests on scale and a move toward profitability. Twist Bioscience guided to fiscal 2026 revenue of USD 456.00 million to USD 457.00 million and targeted adjusted EBITDA breakeven in the fourth fiscal quarter, figures cited by AI Wiki. The third-quarter net loss was USD 35.05 million, so the valuation debate still turns on whether revenue growth converts into durable earnings.

Analyst optimism meets execution risk

TD Cowen's October 13, 2026 target increase followed a rise from USD 115.00 to USD 190.00 and retained a Buy rating. The same report said higher expectations require upcoming results to support the company's execution, making profitability the key counterweight to the target.

Stock trades above EUR 120

Twist Bioscience's primary listing is on Nasdaq, where the stock last stood at USD 139.77 on October 19, 2026, at 4:00 p.m. EDT. Its current market capitalization is USD 9.2 billion, and its 52-week range is USD 23.30 to USD 219.71. The stock's euro indication is EUR 120.18 at Lang & Schwarz on October 20, 2026 at 2:14 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Twist Bioscience stock.